Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Golden Bifid (Inner Mongolia Shuangqi Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Shuangqi Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Golden Bifid** is an orally administered, three-strain live probiotic product manufactured by Inner Mongolia Shuangqi Pharmaceutical. It contains *Bifidobacterium longum*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus* and is intended to modulate intestinal microbiota and support restoration of gut microbial homeostasis. Clinical and preclinical studies have evaluated the product for gastrointestinal disorders, including diarrhea, constipation, diarrhea-predominant irritable bowel syndrome, and slow transit constipation; reported effects include improvement of gastrointestinal symptoms, intestinal motility, gut microbial diversity, and intestinal barrier-associated biology. ([link.springer.com](https://link.springer.com/article/10.1186/s41043-022-00302-0))
- Brand names
- Golden Bifid
- Other names
- Gold bifidumGolden BifidoLive Combined Bifidobacterium and Lactobacillus Tablets双歧杆菌乳杆菌三联活菌片金双歧
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Golden Bifid (Inner Mongolia Shuangqi Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Golden Bifid (Inner Mongolia Shuangqi Pharmaceutical).